ArticleClinics (Sao Paulo, Brazil)2026
Safety and effectiveness of rituximab biosimilar (Rituximab-GP2013) versus originator in rheumatoid arthritis: real-world evidence from a single center.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare the effectiveness, safety, and retention of rituximab biosimilar (RTX-GP2013) and RTX-originator in RTX-naive Rheumatoid Arthritis (RA) patients in a real-world setting.
methodsThis single-center, longitudinal, observational study included 107 RA patients who initiated RTX therapy between January/2010 and September/2023 (40 RTX-GP2013 and 67 RTX-originator). A convenience sample of consecutive eligible RTX-naïve patients was analyzed. Disease activity, treatment retention, and infusion-related reactions were assessed over six months (6M). Multivariate logistic regression identified predictors of low disease activity (CDAI ≤ 10) at 6M.
resultsRTX-GP2013 patients were older (58.3 [53.1-66.4] vs. 54.9 [45.6-60.8], p = 0.029), had longer disease duration (18.4 ± 9.5 vs. 14.7 ± 8.9, p = 0.045), and a greater number of prior biologic therapies (3 [1-5] vs. 1 [0-2], p < 0.001). At 6M, frequency of low disease activity (30.0% vs. 47.8%, p = 0.103), retention rates for a second RTX cycle (77.5% vs. 85.1%, p = 0.433) and mild/moderate infusion-related reactions (17.5% vs. 9.0%, p = 0.231), were comparable between RTX-GP2013 and RTX-originator groups, respectively. Multivariate analysis identified lower baseline disease activity (per 1-point increase in CDAI: OR = 0.93, 95% CI 0.88-0.97, p = 0.003) and fewer prior advanced therapies (OR = 0.56, 95% CI 0.38-0.82, p = 0.003) as predictors of low disease activity at 6M, whereas RTX-GP2013 was not associated with poorer clinical response (OR = 1.85, 95% CI 0.63-5.45, p = 0.265).
conclusionIn this real-world study, RTX-GP2013 and RTX-originator demonstrated comparable effectiveness, safety, and treatment retention in RTX-naive RA patients. Baseline disease activity and fewer prior therapies were predictors of clinical response. These findings reinforce the role of biosimilars in expanding access to effective therapies while maintaining clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.